|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease
| Title: | The Efficacy of Istradefylline for Treating Mild Wearing-Off in Parkinson Disease |
| Other Titles: | The efficacy of istradefylline for treating mild wearing-off in Parkinson's disease |
| Authors: | Yabe, Ichiro Browse this author →KAKEN DB | | Kitagawa, Mayumi Browse this author | | Takahashi, Ikuko Browse this author | | Matsushima, Masaaki Browse this author →ORCID | | Sasaki, Hidenao Browse this author →KAKEN DB |
| Keywords: | Parkinson's disease | | istradefylline | | wearing-off |
| Issue Date: | Nov-2017 |
| Publisher: | Wolters Kluwer Health |
| Journal Title: | Clinical Neuropharmacology |
| Volume: | 40 |
| Issue: | 6 |
| Start Page: | 261 |
| End Page: | 263 |
| Publisher DOI: | 10.1097/WNF.0000000000000249 |
| PMID: | 28976411 |
| Abstract: | Objectives: The adenosine A2A antagonist istradefylline has been used to treat Parkinson disease (PD) with symptoms of wearing-off since 2013 in Japan. Previous randomized controlled trials of istradefylline compared with placebo included PD patients experiencing an average daily OFF time of more than 2 hours. The purpose of this study is to assess the efficacy of 20 mg/d istradefylline in PD subjects experiencing an average daily OFF time of 3 hours or less. Methods: Fifteen patients were enrolled into this retrospective study. They received 20 mg/d istradefylline for 12 weeks. Changes in the Unified Parkinson's Disease Rating Scale part III scores in the ON state (ON-UPDRS-III) scores and daily OFF time were assessed at baseline and after 4, 8, and 12 weeks of administration of istradefylline. Results: At baseline, all subjects had shorter daily OFF times, lower doses of L-DOPA and higher ON-UPDRS-III scores than those in previous randomized controlled trials. Twelve weeks of istradefylline significantly reduced ON-UPDRS-III scores (P < 0.001, Wilcoxon signed rank test). Eleven patients (73%) showed more than 50% reductions in ON-UPDRS-III scores. Improvement of ON-UPDRS-III was significantly correlated with baseline ON-UPDRS-III, and the mean ON-UPDRS-III score at end point was 12.1. Conclusions: Our result suggests that 20 mg/d istradefylline significantly improved motor functions in PD patients with mild wearing-off. |
| Rights: | This is a non-final version of an article published in final form in Clinical Neuropharmacology, Volume 40, Issue 6, 2017, pp.261–263. |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/71786 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 矢部 一郎
|
